Anaplastic large-cell lymphoma with aberrant expression of multiple cytokeratins masquerading as metastatic carcinoma of unknown primary

Journal of Clinical Oncology

Volumn 31, Issue 33, 2013, Pages

  Nguyen, Tudung T ^a   Kreisel, Friederike H ^a   Frater, John L ^a   Bartlett, Nancy L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BRENTUXIMAB VEDOTIN; CA 125 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKERATIN; DOXORUBICIN; PACLITAXEL; PREDNISONE; VINCRISTINE; KERATIN;

ADULT; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER STAGING; CASE REPORT; CLASSICAL HODGKIN LYMPHOMA; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INGUINAL LYMPH NODE; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; LYMPHADENOPATHY; METASTASIS; MIDDLE AGED; NEPHROBLASTOMA; POORLY DIFFERENTIATED CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; CARCINOMA; METABOLISM; PATHOLOGY; LYMPHOMA, LARGE-CELL, ANAPLASTIC; NEOPLASMS, UNKNOWN PRIMARY; SECONDARY;

CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY;

EID: 84892897294     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.7910     Document Type: Article

References (16)

1. Stein H, Mason DY, Gerdes J, et al: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858, 1985 (Pubitemid 15242469)
2. Fornari A, Piva R, Chiarle R, et al: Anaplastic large cell lymphoma: One or more entities among T-cell lymphoma? Hematol Oncol 27:161-170, 2009
3. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al: ALK-negative systemic anaplastic large cell lymphoma: Differential diagnostic and prognostic aspects - A review. J Pathol 200:4-15, 2003 (Pubitemid 36592630)
4. Kamel OW, Rouse RV, Warnke RA: Heterogeneity of epithelial marker expression in routinely processed, poorly differentiated carcinomas. Arch Pathol Lab Med 115:566-570, 1991
5. Spagnolo DV, Michie SA, Crabtree GS, et al: Monoclonal anti-keratin (AE1) reactivity in routinely processed tissue from 166 human neoplasms. Am J Clin Pathol 84:697-704, 1985 (Pubitemid 16213281)
6. Gustmann C, Altmannsberger M, Osborn M, et al: Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin's lymphomas. Am J Pathol 138:1413-1422, 1991
7. Adams H, Schmid P, Dirnhofer S, et al: Cytokeratin expression in hematological neoplasms: A tissue microarray study on 866 lymphoma and leukemia cases. Pathol Res Pract 204:569-573, 2008
8. Bovio IM, Allan RW: The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK anaplastic large cell lymphomas. Am J Clin Pathol 130:628-634, 2008
9. Savage KJ, Harris NL, Vose JM, et al: ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008
10. Delsol G, Al Saati T, Gatter KC, et al: Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas: Diagnostic value in so-called malignant histiocytosis. Am J Pathol 130:59- 70, 1988 (Pubitemid 18044833)
11. Menasce LP, Eyden B: Nasopharyngeal carcinoma mimicking large-cell anaplastic lymphoma. Histopathology 46:342-344, 2005 (Pubitemid 40343182)
12. Eyden B, Chakrabarty B, Hatimy U: Carcinoma versus cytokeratin-positive lymphoma: A case report emphasizing the diagnostic role of electron microscopy. Ultrastruct Pathol 33:33-38, 2009
13. Massard C, Loriot Y, Fizazi K: Carcinomas of an unknown primary origin: Diagnosis and treatment. Nat Rev Clin Oncol 8:701-710, 2011
14. Pavlidis N, Pentheroudakis G: Cancer of unknown primary site. Lancet 379:1428-1435, 2012
15. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821, 2010
16. Pro B, Advani R, Brice P, et al: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol 30:2190-2196, 2012